UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2021

Seelos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-22245

 

87-0449967

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

300 Park Avenue, 2nd Floor, New York, NY

 

10022

(Address of principal executive offices)

 

(Zip Code)

Registrant's telephone number, including area code: (646) 293-2100

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SEEL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      ☐     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐     



Item 1.02.    Termination of a Material Definitive Agreement.

On December 17, 2020, Seelos Therapeutics, Inc. ("Seelos") filed a Current Report on Form 8-K with the Securities and Exchange Commission stating that, on December 11, 2020, Seelos entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Lind Global Asset Management II, LLC (the "Investor") pursuant to which, among other things, on December 11, 2020, Seelos issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (a) a convertible promissory note (the "Note") in an aggregate principal amount of $12,000,000, which would bear no interest and mature on December 11, 2022, and (b) 975,000 shares of common stock of Seelos (the "Common Stock"). Following the issuance of the Note, Seelos paid certain amounts to the Investor in cash against the Note obligation.

On June 14, 2021, Seelos and the Investor entered into an Acknowledgment and Termination Agreement (the "Termination Agreement"), pursuant to which Seelos agreed to issue to the Investor an aggregate of 406,250 additional shares of Common Stock (the "Shares") and pay the Investor an additional aggregate of $790,804 (the "Final Payment") in full satisfaction of Seelos' remaining obligations to the Investor under the Note. Seelos has issued the Shares and made the Final Payment to the Investor. Accordingly, the Securities Purchase Agreement and the Note have terminated, effective June 15, 2021.

The foregoing summary of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to a copy of the Termination Agreement filed herewith as Exhibit 10.1.

Item 2.04.    Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The information set forth in Item 1.02 of this Current Report on Form 8-K is incorporated herein by reference into this Item 2.04.

Item 3.02.    Unregistered Sales of Equity Securities.

The information set forth in Item 1.02 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02.

The Shares were offered and sold to the Investor on June 14, 2021 in a transaction exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on Section 3(a)(9) or 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Accordingly, the Shares have not been registered under the Securities Act and the Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

     

Number

  

Description

     

10.1+

  

Acknowledgment and Termination Agreement, dated as of June 14, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management II, LLC.

     

+

  

Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Seelos hereby undertakes to furnish supplementally copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission.

 

*   *   *  

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Seelos Therapeutics, Inc.

 

 

 Date: June 17, 2021

By:

/s/ Raj Mehra, Ph.D.

 

 

 

Name: Raj Mehra, Ph.D.

 

 

 

Title: Chief Executive Officer, President and Interim Chief Financial Officer

 

 

 

 


 

Exhibit 10.1

ACKNOWLEDGMENT AND TERMINATION AGREEMENT

     THIS ACKNOWLEDGMENT AND TERMINATION AGREEMENT (this "Agreement") is made and entered into as of June 14, 2021, by and between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and Lind Global Asset Management II, LLC, a Delaware limited liability company ("Lind" and, together with the Company, the "Parties").

RECITALS

     WHEREAS, the Parties are parties to that certain: (a) Securities Purchase Agreement entered into as of December 11, 2020 (the "Purchase Agreement"); (b) Security Agreement, dated December 11, 2020 (the "Security Agreement"); and (c) Patent Security Agreement entered into as of December 11, 2020 (the "Patent Security Agreement");

     WHEREAS, pursuant to the Purchase Agreement, the Company issued that certain Convertible Promissory Note due December 11, 2022 (Note No. CN-1), dated December 11, 2020 (the "Note" and, together with the Purchase Agreement, the Security Agreement and the Patent Security Agreement, the "Loan Agreements") in favor of Lind, which had an initial principal amount of $12 million;

     WHEREAS, the Company has made the following payments to Lind against the Company's obligations under the Note: (a) on January 8, 2021, the Company made a payment of $1,407,395.66 to Lind; (b) on February 3, 2021, the Company made a second payment of $3,347,000.00 to Lind; and (c) on May 24, 2021, the Company made a third payment of $6,454,800.00 to Lind, for total payments of $11,209,195.66 as of the date of this Agreement (collectively, the "Total Payments"); and

     WHEREAS, the Parties wish to provide for the final satisfaction of the Company's obligations under the Note and, upon such satisfaction, terminate the Loan Agreements and each Party's respective obligations thereunder.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:

ARTICLE I

AMENDMENT AND TERMINATION OF THE LOAN AGREEMENTS

     1.1     Acknowledgements. The Parties acknowledge and agree that the Total Payments have been made by the Company and received by Lind. The Total Payments shall be retained by Lind as payments against the Company's obligations under the Note.

     1.2     Additional Payment and Share Issuance. On or before the date that is five (5) business days from the date of this Agreement, the Company shall (a) pay Lind an additional amount of $790,804.34 in immediately available funds, pursuant to the wire instructions attached as Exhibit A hereto (the "Additional Payment"), and (b) issue Lind an aggregate of 406,250 shares of the Company's common stock (the "Share Issuance"; the common stock to be


received in connection with the Share Issuance is hereinafter referred to as the "Subject Shares"; the receipt by Lind of the Additional Payment and the Subject Shares in accordance with the terms of this Section 1.2 is hereinafter referred to as the "Payoff Conditions"). The Subject Shares shall not bear any legend restricting Lind's ability to sell or otherwise transfer such shares. On or prior to the Satisfaction Date (as defined below), (a) Lind shall deliver to counsel to the Company a customary "Rule 144" seller's representation letter with respect to the Subject Shares and the Closing Shares (as such term is defined in the Purchase Agreement) in the form attached hereto as Exhibit B, and (b) the Company shall cause its counsel to issue a legal opinion, and the Company shall deliver any necessary instruction or other documentation, to the Company's transfer agent directing the transfer agent to remove any legends affixed to the Subject Shares and the Closing Shares (as such term is defined in the Purchase Agreement). In furtherance of the foregoing, each of the Parties acknowledges and agrees that the Subject Shares are being issued in exchange for, among other things, the Note, without any additional renumeration, pursuant to Section 3(a)(9) of the Securities Act.

     1.3     Agreement. The Parties agree that upon Lind's receipt of the Additional Payment and the Subject Shares (the date on which Lind receives such Additional Payment and Subject Shares is hereinafter referred to as the "Satisfaction Date"), (a) each of the Loan Agreements (excluding any survival provisions expressly contained therein) and any liens, security interests or other encumbrances held by or granted in favor of Lind to secure the Company's obligations under the Loan Agreements shall be deemed terminated in its entirety and of no further force or effect, (b) all liabilities, obligations and indebtedness owing by Lind under the Loan Agreements, other than those liabilities and obligations (including, without limitation, indemnification obligations) that by the express terms of any Loan Agreement survive the repayment in full of the obligations and the performance of the Company's other obligations thereunder (such obligations being the "Surviving Obligations") shall be released, discharged and satisfied in full; and (c) Lind shall be deemed to have satisfied all of its obligations to the Company under the Loan Agreements.

     1.4     Releases and Termination Statements. At the expense of the Company, (a) Lind will, promptly upon (but in any event within five (5) business days following) satisfaction of each of the Payoff Conditions, authorize the Company (or any designee of the Borrower) to file the UCC-3 termination statement in the form attached hereto as Exhibit C to terminate all security interests and liens granted to Lind under the Security Agreement, and (b) Lind will, promptly upon (but in any event within five (5) business days following) the request by the Company following satisfaction of each of the Payoff Conditions, execute and deliver to the Company (or any designee of the Company), any other such lien releases and discharges of security interests, and other similar discharge or release documents, as are reasonably requested and necessary to release, as of record, the security interests and all notices of security interests and liens previously filed by Lind under the Loan Agreements (including, without limitation, any releases required to be filed with the United States Patent and Trademark Office or with the United States Copyright Office, to the extent applicable, and return of any possessory collateral delivered by the Company to Lind). Upon satisfaction of each of the Payoff Conditions and written confirmation thereof from Lind to the Company (which shall be provided by Lind to the Company within five (5) business days after the Payoff Conditions have been satisfied), Lind authorizes the Company (or any designee of the Company) to prepare and file the UCC-3 termination statements in agreed form as attached hereto as Exhibit C.

2


     1.5     Reinstatement. Notwithstanding the termination of the Loan Agreements or anything to the contrary contained in any releases provided for herein or in other documents, all Surviving Obligations of the Company under or in respect of the Loan Agreements which by their terms are intended to survive the repayment of obligations of the Company and the performance of its obligations under the Loan Agreements shall continue in full force and effect. In furtherance thereof, the Company acknowledges and agrees that its obligations and liabilities under the Loan Agreements shall be reinstated with full force and effect solely to the extent that, at any time on or after the Satisfaction Date, all or any portion of the Additional Payment or any other amounts received by Lind under any of the Loan Agreements, or any of the Subject Shares is voided or rescinded or must otherwise be returned by Lind to the Company upon the Company's insolvency, bankruptcy or reorganization or otherwise.

ARTICLE II

MISCELLANEOUS

     2.1.     Interpretation. The words "hereof," "herein" and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Whenever the word "including" is used in this Agreement, it shall be deemed to be followed by the words "without limitation." No provision of this Agreement shall be construed to require Lind or the Company or any of their respective subsidiaries, affiliates, assigns, or representatives to take any action that would violate any applicable law.

     2.2.     Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Agreement will not in any way be affected or impaired thereby.

     2.3.     Amendments and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by both Parties, or their assigns where applicable.

     2.4.     Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the Parties acknowledge have been merged into this Agreement. The Parties acknowledge and agree that neither of the Parties has made any representation or promise in connection with this Agreement that is not contained herein.

     2.5.     Parties in Interest. This Agreement shall be binding upon, and inure to the benefit of and be enforceable by, each of the Parties and their respective successors and assigns.

3


     2.6.     Capacity and Authorization. The Parties agree that the persons executing this Agreement on behalf of the Parties have the necessary and appropriate authority and capacity to execute, deliver, and perform this Agreement, and that this Agreement is enforceable in accordance with its terms. The Parties agree that this Agreement is fully and adequately supported by consideration and is fair and reasonable. The Parties further agree that each Party has: (a) had the opportunity to consult with legal counsel of its choice as such party may have desired with respect to all matters resolved herein; (b) participated fully in the negotiation and preparation of this Agreement; and (c) carefully reviewed this Agreement and is entering into same freely. Accordingly, this Agreement shall not be more strictly construed against either Party.

     2.7.     Confidentiality. The Parties agree and understand that the terms and conditions of this Agreement shall remain confidential, and shall not be disclosed to any third party for any purpose whatsoever; provided, however, that nothing in this Agreement shall prevent the Parties from making any disclosure required by law.

     2.8.     Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, without reference to principles of conflict of laws or choice of laws.

     2.9.     Counterparts. This Agreement may be executed in in two identical counterparts, both of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the other Party. Signature pages delivered by facsimile or e-mail shall have the same force and effect as an original signature

[Signature Page Follows]

 

 

 

 

4


     IN WITNESS WHEREOF, Lind and the Company have caused this Termination Agreement to be duly executed as of the day and year first above written.

THE COMPANY:

SEELOS THERAPEUTICS, inc.

 

By: /s/ Raj Mehra, Ph.D.
     Name: Raj Mehra, Ph.D.
     Title: Chief Executive Officer

 

LIND:

LIND GLOBAL ASSET MANAGEMENT II, LLC

 

By: /s/ Jeff Easton
     Name: Jeff Easton
     Title: Authorized Signatory

 

 

 

[SIGNATURE PAGE TO TERMINATION AGREEMENT]